KAPPA-OPIOID EFFECTS ON FETAL BEHAVIOR - CENTRAL ADMINISTRATION OF U50,488

被引:17
|
作者
PETROV, ES
VARLINSKAYA, EI
ROBINSON, SR
SMOTHERMAN, WP
DECOSTA, BR
RICE, KC
机构
[1] SUNY BINGHAMTON,DEPT PSYCHOL,CTR DEV PSYCHOBIOL,PERINATAL NEUROETHOL LAB,BINGHAMTON,NY 13902
[2] RUSSIAN ACAD MED SCI,INST EXPTL MED,DEPT PAVLOVIAN PHYSIOL,ST PETERSBURG,RUSSIA
[3] NIDDKD,MED CHEM LAB,BETHESDA,MD 20892
关键词
U50,488; NOR-BINALTORPHIMINE; KAPPA; OPIOID; RAT FETUS;
D O I
10.1016/0031-9384(94)90276-3
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
The kappa opioid agonist U50,488 was administered to E21 rat fetuses via intracisternal (IC), intrahemispheric (IH), or intrathecal (IT) injection. The IC administration of U50,488 promoted a threefold increase in motor activity, which was predominated by movements of caudal regions of the body (rearlimbs, body trunk, and tail). The agonist effect was reversed by IC administration of the selective kappa opioid antagonist nor-binaltorphimine. The IH injection of U50,488 had little effect on fetal behavior, but IT injection resulted in pronounced increases in fetal activity, including rearlimb, trunk and tail movements. The IT administration of nor-binaltorphimine blocked U50,488 effects, whereas IH injection of the antagonist had little influence on fetal behavior. These findings suggest that kappa opioid receptors located in the spinal cord may play a role in the regulation of fetal motor behavior.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [31] RENAL RESPONSES TO INTRACEREBROVENTRICULAR (ICV) ADMINISTRATION OF KAPPA OPIOID AGONIST, U50, 488, IN CONSCIOUS RATS
    KAPUSTA, DR
    OBIH, JC
    FASEB JOURNAL, 1992, 6 (04): : A1166 - A1166
  • [32] Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H
    Alicea, C
    Belkowski, S
    Eisenstein, TK
    Adler, MW
    Rogers, TJ
    JOURNAL OF NEUROIMMUNOLOGY, 1996, 64 (01) : 83 - 90
  • [33] THE KAPPA-OPIOID RECEPTOR AGONIST U50,488H INDUCES ACUTE PHYSICAL-DEPENDENCE IN GUINEA-PIGS
    BRENT, PJ
    CHAHL, LA
    CANTARELLA, PA
    KAVANAGH, C
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 241 (2-3) : 149 - 156
  • [34] EFFECT OF CHRONIC ADMINISTRATION OF NALTREXONE ON BRAIN MU-OPIOID AND KAPPA-OPIOID RECEPTORS AND RESPONSES TO U-50,488H, A KAPPA-OPIOID RECEPTOR AGONIST IN THE MOUSE
    VILLAR, VM
    RAHMANI, NH
    BHARGAVA, HN
    FASEB JOURNAL, 1995, 9 (03): : A102 - A102
  • [35] Modulation of DPK cell function by the kappa opioid agonist U50,488H
    Guan, LM
    Eisenstein, TK
    Adler, MW
    Rogers, TJ
    DRUGS OF ABUSE, IMMUNOMODULATION, AND AIDS, 1998, 437 : 125 - 136
  • [36] STRUCTURE-ACTIVITY-RELATIONSHIP PERTAINING TO THE NORTH-WEST REGION OF THE KAPPA-OPIOID AGONIST, U-50,488
    ZHAO, S
    FREEMAN, JP
    VONVOIGTLANDER, PF
    HOWE, WJ
    SZMUSZKOVICZ, J
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (17) : 2139 - 2144
  • [37] Sex differences in opioid antinociception in rhesus monkeys: Antagonism of fentanyl and U50,488 by quadazocine
    Negus, SS
    Zuzga, DS
    Mello, NK
    JOURNAL OF PAIN, 2002, 3 (03): : 218 - 226
  • [38] CHANGES IN REGIONAL GLUCOSE-METABOLISM AND BEHAVIOR FOLLOWING INTRANIGRAL APPLICATION OF THE KAPPA-OPIATE AGONIST U50,488
    HOHMANN, AG
    CLEMENT, RW
    WALKER, JM
    REGULATORY PEPTIDES, 1994, : S257 - S258
  • [39] Blockade of ethanol reward by the kappa opioid receptor agonist U50,488H
    Logrip, Marian L.
    Janak, Patricia H.
    Ron, Dorit
    ALCOHOL, 2009, 43 (05) : 359 - 365
  • [40] Sodium channel blocking actions of the κ-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects
    Su, X
    Joshi, SK
    Kardos, S
    Gebhart, GF
    JOURNAL OF NEUROPHYSIOLOGY, 2002, 87 (03) : 1271 - 1279